arrow
V

Vincent van der Noort

stichting het nederlands kanker instituut-antoni van leeuwenhoek ziekenhuis
H指数:30
被引数:4,825

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol

曲美替尼用于NRAS突变肿瘤:药物重定位计划的结果

2026-06-010
PRE
Prospective evaluation of genomics-guided off-label treatment

基因组指导的标签外治疗的预期评估

Nature
IF48.5
2026-04-150
OA
Stage I non-small cell lung cancer: improving patient selection for minimally invasive lobectomy or stereotactic ablative radiotherapy based on clinical characteristics

I期非小细胞肺癌:基于临床特征改进患者选择,以进行微创肺叶切除术或立体定向消融放射治疗

2026-01-080
PRE
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study

帕博利珠单抗联合仑伐替尼作为恶性胸膜间皮瘤患者的二线治疗方案(PEMMELA研究):一项单臂、II期研究的队列2

2025-11-240
PRE
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial

与健康相关的生活质量:在晚期乳腺癌中,比较一线与二线CDK4/6抑制剂使用的SONIA试验结果

2025-11-210
PRE
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: a cost-effectiveness analysis of the phase 3 SONIA trial

CDK4/6抑制剂在晚期乳腺癌一线与二线治疗中的健康经济学结果和成本:SONIA III期试验的成本效益分析

2025-10-250
OAAI
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

奥拉帕利用于携带同源重组修复基因突变的肿瘤患者:来自药物再发现方案的结果

2025-10-160
OAAI
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial

新辅助伊匹木单抗和纳武利尤单抗在可切除皮肤鳞状细胞癌中的应用:一项随机Ⅱ期临床试验

2025-10-080
OAAI
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis

卡巴他赛与阿比特龙或恩扎卢胺治疗既往多西他赛治疗后的不良预后转移性去势抵抗性前列腺癌:一项含循环肿瘤DNA分析的II期试验

2025-09-300
OAAI
Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

作者更正: 在晚期乳腺癌中早期使用CDK4/6抑制剂与延迟使用

Nature
IF48.5
2025-07-220
PRE
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer

表观遗传谱分析鉴定了内分泌抵抗的标志物及转移性去势抵抗性前列腺癌的治疗选择

2025-07-020
OAAI
Reply to Letter to the Editor “Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study” by Liu et al., G. Rocco, and Szarpak et al.

回复致编辑函“通过电子鼻分析呼出气检测肺癌:一项多中心前瞻性外部验证研究”由Liu等人、G. Rocco和Szarpak等人撰写。

2025-06-020
PRE
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study

帕博利珠单抗混合剂量方案不劣于固定剂量方案在晚期非小细胞肺癌中的疗效:一项真实世界、回顾性双中心队列研究

2025-02-061
OA
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol

克唑替尼治疗MET突变的非小细胞肺癌的安全性、有效性和生物标志物分析 -- 来自药物再发现方案的结果

2024-10-010
PRE
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
2024-07-180
PRE